Antibiotic use in public hospitals in Vietnam between 2018 and 2022: a retrospective study.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 39122394.
- Also identified by DOI 10.1136/bmjopen-2024-087322 and PMC identifier 11331946.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess the patterns of antibiotic consumption and expenditure in Vietnam. This was a cross-sectional study. This study used data of antibiotic procurement that was publicly announced from 2018 to 2022 as a proxy for antibiotic consumption. This study included winning bids from 390 procurement units in 63 provinces in Vietnam for 5 years with a total expenditure of US$ 12.8 billions that represented for approximately 20-30% of the national funds spend on medicines. Antibiotics were classified by WHO AWaRe (Access, Watch and Reserve) classification. The primary outcomes were the proportions of antibiotic consumptions in number of defined daily doses (DDD) and expenditures. There was a total of 2.54 million DDDs of systemic antibiotics, which accounted for 24.7% (US $3.16 billions) of total expenditure for medicines purchased by these public health facilities. The overall proportion of Access group antibiotics ranges from 40.9% to 53.8% of the total antibiotic consumption over 5 years. This analysis identifies an unmet target of at least 60% of the total antibiotic consumption being Access group antibiotics and an unreasonable share of expenditure for non-essential antibiotics in public hospitals in Vietnam.
Medical subject headings
- Anti-Bacterial Agents
- Hospitals, Public